Evofem Biosciences, Inc.

For the period ended Mar 31, 2026. Filed May 15, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 15, 2026

EVFM$0.48-23.4%Stored close · as of Aug 10, 2022

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except par value and share data)

	As of
March 31, 2026 · December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$1,491	$	-
Restricted cash and cash equivalents	888		578
Trade accounts receivable, net	560		12,480
Inventories	1,890		1,129
Prepaid and other current assets	1,227		1,097
Total current assets	6,056		15,284
Property and equipment, net	416		418
Operating lease right-of-use assets	150		182
Intangible asset, net (Note 7)	778		4,348
Other noncurrent assets	42		42
Total assets	$7,442		$20,274
Liabilities, convertible and redeemable preferred stock and stockholders’ deficit
Current liabilities:
Accounts payable	$12,003		$13,153
Notes - carried at fair value (Note 4)	18,080		20,097
Notes - carried at fair value - related party (Note 4)	843		1,352
Convertible notes - Adjuvant - related party (Note 4)	33,384		32,770
Short-term debt	-		147
Accrued expenses	1,205		1,292
Accrued compensation	1,495		2,587
Operating lease liabilities – current	123		128
Derivative liabilities	1,168		1,006
Contingent liabilities - current (Note 7)	220		272
Other current liabilities	10,231		12,016
Total current liabilities	78,752		84,820
Operating lease liabilities – noncurrent	27		54
Contingent liabilities - noncurrent (Note 7)	1,375		4,837
Total liabilities	80,154		89,711
Commitments and contingencies (Note 7)
Convertible and redeemable preferred stock, $0.0001 par value, senior to Common Stock
Series E-1, F-1 and G-1 convertible and redeemable preferred stock, 10,000, 95,000 and 5,000 shares authorized; 2,588 and 2,412 shares of E-1 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively; 26,280 shares of F-1 issued and outstanding at both March 31, 2026 and December 31, 2025, and 1,561 and 1,618 shares of G-1 issued and outstanding at March 31, 2026 and December 31, 2025, respectively	4,918		4,899
Stockholders’ deficit:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of both March 31, 2026 and December 31, 2025	-		-
Common Stock, $0.0001 par value; 3,000,000,000 shares authorized; 132,530,081 and 126,685,925 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	13		13
Additional paid-in capital	831,875		831,859
Accumulated other comprehensive loss	(6,643)		(8,818)
Accumulated deficit	(902,875)		(897,390)
Total stockholders’ deficit	(77,630)		(74,336)
Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit	$7,442		$20,274

See accompanying notes to the condensed consolidated financial statements (unaudited).

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.